UNITY Biotechnology   Report issue

For profit Phase 2
Founded: Brisbane CA United States (2009)

Organization Overview

First Clinical Trial
2018
NCT03513016
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Unity Biotechnology | UNITY Biotechnology | Unity Biotechnology, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

aflibercept (zaltrap) (2 trials)

ubx0101 (3 trials)

ubx1325 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 1)

Macular Edema (Phase 1)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 3